Korro Bio (KRRO)
NASDAQ:KRRO
KRRO Stock Chart & Stats
$14.00
-$1.03(-2.68%)
At close: 4:00 PM EST
$14.00
-$1.03(-2.68%)
Day’s Range― - ―
52-Week Range$5.20 - $55.89
Previous CloseN/A
Volume28.02K
Average Volume (3M)734.66K
Market Cap
$201.92M
Enterprise Value$153.26M
Total Cash (Recent Filing)$75.16M
Total Debt (Recent Filing)$43.49M
Price to Earnings (P/E)―
Beta2.74
Next Earnings
May 19, 2026EPS Estimate
-1.73Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-5.33
Shares Outstanding14,422,571
10 Day Avg. Volume1,808,258
30 Day Avg. Volume734,659
Financial Highlights & Ratios
PEG Ratio-0.02
Price to Book (P/B)1.46
Price to Sales (P/S)11.77
P/FCF Ratio-0.95
Enterprise Value/Market Cap0.76
Enterprise Value/Revenue23.98
Enterprise Value/Gross Profit26.69
Enterprise Value/Ebitda-1.87
Forecast
1Y Price Target
$19.75Price Target Upside41.07% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering9
EPS Forecast (FY)-8.05
Revenue Forecast (FY)$2.20M
Bulls Say, Bears Say
Bulls Say
Delivery ApproachAnalyst highlights the shift to GalNAc-conjugated delivery, which demonstrated highly liver-selective distribution in non-human primates with minimal off-target exposure and could improve likelihood of clinical translation.
Financing And RunwayAnalyst points out an oversubscribed private placement that extended the company's cash runway and increased visibility to advance clinical programs without immediate financing pressure.
Preclinical EfficacyAnalyst notes preclinical studies showed KRRO-121 stabilized glutamine synthetase and reduced ammonia across multiple animal models, supporting a strong biological rationale for treating urea cycle disorders and hepatic encephalopathy.
Bears Say
Capital And Dilution RiskAnalyst cautions that limited cash runway and the need for additional capital to fund clinical development create potential dilution risk for existing shareholders.
Clinical Execution RiskAnalyst warns that disappointing results from a lipid nanoparticle-delivered program suggest delivery failures rather than editing inefficacy, increasing risk around first-in-human dosing and dose durability.
Partnerships And RevenueAnalyst notes a pause in the collaboration with Novo Nordisk that reduced collaboration revenue and could slow progress in partnered development efforts.
Korro Bio News
KRRO FAQ
What was Korro Bio’s price range in the past 12 months?
Korro Bio lowest stock price was $5.20 and its highest was $55.89 in the past 12 months.
What is Korro Bio’s market cap?
Korro Bio’s market cap is $201.92M.
When is Korro Bio’s upcoming earnings report date?
Korro Bio’s upcoming earnings report date is May 19, 2026 which is in 43 days.
How were Korro Bio’s earnings last quarter?
Korro Bio released its earnings results on Mar 12, 2026. The company reported -$5.33 earnings per share for the quarter, missing the consensus estimate of -$2.07 by -$3.26.
Is Korro Bio overvalued?
According to Wall Street analysts Korro Bio’s price is currently Undervalued.
Does Korro Bio pay dividends?
Korro Bio does not currently pay dividends.
What is Korro Bio’s EPS estimate?
Korro Bio’s EPS estimate is -1.73.
How many shares outstanding does Korro Bio have?
Korro Bio has 14,422,571 shares outstanding.
What happened to Korro Bio’s price movement after its last earnings report?
Korro Bio reported an EPS of -$5.33 in its last earnings report, missing expectations of -$2.07. Following the earnings report the stock price went up 11.304%.
Which hedge fund is a major shareholder of Korro Bio?
Currently, no hedge funds are holding shares in KRRO
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Korro Bio Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$19.75 (41.07% Upside)
$19.75 (41.07% Upside)
Hedge Fund Trend
Decreased
By 681.3K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Bought Shares
Worth $20.7M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Neutral
Last 7 Days ▼ 0.9%
Last 30 Days ▲ 1.8%
Last 30 Days ▲ 1.8%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-88.72%
12-Months-Change
Fundamentals
Return on Equity
-115.95%
Trailing 12-Months
Asset Growth
-48.86%
Trailing 12-Months
Company Description
Korro Bio
Korro Bio, Inc., a biopharmaceutical company, discovers, develops, and commercializes genetic medicines based on editing RNA for the treatment of rare and highly prevalent diseases. Korro Bio, Inc. is based in Cambridge, Massachusetts.
KRRO Stock 12 Month Forecast
Average Price Target
$19.75
▲(41.07% Upside)
Technical Analysis
Assembly Biosciences
―
Annexon Biosciences
―
4D Molecular Therapeutics
―
Design Therapeutics
―
Aura Biosciences Inc
―